21^st International Conference on Breast Pathology and Cancer Diagnosis June 13-14, 2024 Rome, Italy

Track-1: Molecular Pathology: Unraveling Breast Cancer Subtypes

This track focuses on the latest advancements in molecular pathology techniques and their application in unraveling the intricate subtypes of breast cancer. With the advent of genomic profiling and molecular markers, this session aims to explore the diverse molecular landscapes that underlie breast cancer, including hormone receptor-positive, HER2-positive, and triple-negative subtypes. Experts will discuss the molecular signatures, genomic alterations, and gene expression profiles associated with these subtypes, enabling a deeper understanding of their unique characteristics and implications for prognosis and treatment. Attendees will gain insights into the evolving field of molecular pathology, its impact on breast cancer classification, and the potential for personalized therapeutic interventions.

Track-2: Diagnostic Challenges: From Atypical Ductal Hyperplasia to Ductal Carcinoma In Situ

This track focuses on the diagnostic challenges encountered in the spectrum of breast lesions, specifically from atypical ductal hyperplasia (ADH) to ductal carcinoma in situ (DCIS). With the increasing use of and detection techniques, the identification and accurate diagnosis of these lesions have become crucial for appropriate patient management. This track explores the complexities involved in distinguishing between ADH and DCIS, discussing the overlapping morphological features, immunohistochemical markers, and molecular characteristics that aid in differential diagnosis. The track also highlights the latest advancements in diagnostic tools, including genomic profiling and molecular testing, aiming to enhance diagnostic accuracy and guide optimal treatment strategies for patients with ADH and DCIS.

Track-3: Precision Medicine in Breast Pathology: Integrating Genomics and Targeted Therapies

Precision Medicine in Breast Pathology: Integrating Genomics and Targeted Therapies delves into the transformative potential of precision medicine approaches in breast cancer diagnosis and treatment. This track focuses on the integration of genomics, molecular profiling, and advanced technologies to identify specific genetic alterations and biomarkers that guide targeted therapies. Experts will present cutting-edge research on genomic profiling techniques, such as next-generation sequencing and gene expression profiling, and their implications in personalized treatment strategies. Discussions will revolve around the efficacy and limitations of targeted therapies, including hormone therapy, HER2-targeted therapy, and emerging immunotherapies. This track aims to highlight the latest breakthroughs in precision medicine, emphasizing its role in optimizing patient outcomes and shaping the future of breast cancer management.

Track-4: Immunohistochemistry and Biomarkers in Breast Pathology

The track on "Immunohistochemistry and Biomarkers in Breast Pathology" focuses on the critical role of immunohistochemistry (IHC) and biomarkers in the diagnosis, prognosis, and treatment of breast pathology. This track explores the latest advancements in IHC techniques, including the identification and evaluation of key biomarkers such as hormone receptors (ER, PR), HER2/neu, Ki-67, and other emerging markers. Discussions will revolve around their clinical significance, interpretation challenges, and their impact on therapeutic decision-making. Additionally, this track will delve into novel biomarkers and their potential for risk assessment, predicting treatment response, and guiding personalized treatment strategies. Attendees will gain insights into the evolving landscape of IHC and biomarkers, enhancing their understanding of breast pathology evaluation and patient management.

Track-5: Breast Imaging: Innovations in Radiology and Pathology Correlation

The track "Breast Imaging: Innovations in Radiology and Pathology Correlation" focuses on the latest advancements in imaging techniques for breast pathology and the correlation between radiological findings and pathological assessment. This track will delve into cutting-edge innovations in breast imaging, such as digital mammography, tomosynthesis, magnetic resonance imaging (MRI), and molecular imaging modalities. Discussions will revolve around the integration of imaging findings with pathological analysis to enhance diagnostic accuracy, improve treatment planning, and optimize patient outcomes. Attendees will gain insights into the evolving field of breast imaging, explore the challenges and opportunities in radiology-pathology correlation, and understand the implications for clinical decision-making in breast pathology.

Track-6: Pathology of Triple-Negative Breast Cancer: Clinical Implications and Therapeutic Strategies

Triple-negative breast cancer (TNBC) represents a unique subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This track will delve into the intricate pathology of TNBC, exploring its clinical implications and therapeutic strategies. Attendees will gain insights into the aggressive nature of TNBC, its distinct molecular features, and the challenges associated with diagnosis and treatment. Discussion will focus on emerging biomarkers, novel targeted therapies, and immunotherapy approaches. By understanding the underlying pathology of TNBC, participants will be equipped to optimize patient management, improve prognostic evaluation, and contribute to the development of personalized therapeutic interventions.

Track-7: Emerging Technologies in Breast Pathology: Digital Pathology, AI, and Machine Learning

"Emerging Technologies in Breast Pathology: Digital Pathology, AI, and Machine Learning" explores the transformative potential of cutting-edge technologies in breast pathology. This track focuses on digital pathology, which enables the digitization of histopathology slides for improved storage, accessibility, and collaboration. It delves into the utilization of artificial intelligence (AI) and machine learning algorithms for tasks such as image analysis, lesion detection, and prognostic prediction in breast pathology. Attendees will gain insights into the latest advancements, challenges, and opportunities associated with these technologies, their integration into routine practice, and their potential to enhance accuracy, efficiency, and personalized patient care in the field of breast pathology.

Track-8: Benign Breast Lesions: Diagnosis, Management, and Surveillance

Benign Breast Lesions: Diagnosis, Management, and Surveillance focuses on the diagnosis, management, and surveillance of benign breast lesions. Benign breast lesions are common findings in clinical practice, and accurate diagnosis is crucial to distinguish them from malignant counterparts. This track delves into the latest advancements in diagnostic techniques, including imaging modalities, biopsy approaches, and pathological assessment. It also explores the management strategies for benign breast lesions, ranging from conservative observation to surgical interventions, and discusses the long-term surveillance and follow-up considerations. Attendees will gain insights into the optimal management strategies, risk assessment tools, and the evolving landscape of benign breast lesion diagnosis, ensuring improved patient care and outcomes.

Track-9: Breast Pathology in Pregnancy and Lactation: Challenges and Considerations

Breast Pathology in Pregnancy and Lactation: Challenges and Considerations focuses on the unique challenges and considerations involved in diagnosing and managing breast pathology during pregnancy and lactation. Pregnancy and lactation introduce hormonal changes and physiological adaptations in the breast, making the evaluation and interpretation of breast lesions more complex. This track aims to explore the impact of pregnancy and lactation on breast pathology, including the diagnosis of benign and malignant breast lesions, the safety of imaging modalities and biopsy techniques, hormonal influences on tumor behavior, and the implications for treatment decisions. The discussions will provide valuable insights to pathologists, radiologists, obstetricians, and oncologists involved in the care of pregnant and lactating patients with breast pathology.

Track-10: Metastatic Breast Cancer: Pathological Insights and Treatment Approaches

"Metastatic Breast Cancer: Pathological Insights and Treatment Approaches," focuses on the critical aspects of metastatic breast cancer from a pathological perspective. It aims to provide a deeper understanding of the underlying mechanisms of metastasis, the molecular characteristics associated with metastatic breast cancer, and the challenges in diagnosing and classifying metastatic lesions. Additionally, this track explores the latest advancements in treatment approaches for metastatic breast cancer, including targeted therapies, immunotherapies, and emerging treatment modalities. Through insightful presentations and discussions, attendees will gain valuable insights into the pathological features of metastatic breast cancer and the evolving landscape of treatment options for improved patient outcomes.

Track-11: Pathological Assessment of Breast Core Biopsies: Pitfalls and Best Practices

This track focuses on the crucial topic of "Pathological Assessment of Breast Core Biopsies: Pitfalls and Best Practices." It aims to address the challenges encountered during the evaluation of breast core biopsies and explore the optimal strategies for accurate diagnosis. The track will delve into common pitfalls, such as sampling errors, inadequate tissue acquisition, and interpretation challenges. It will highlight the importance of incorporating ancillary studies, including immunohistochemistry and molecular testing, to enhance diagnostic accuracy. Experts in breast pathology will share their experiences; discuss quality assurance measures, and present best practices for evaluating breast core biopsies, ultimately improving patient care and treatment decision-making.

Track-12: Inflammatory Breast Cancer: Pathogenesis, Diagnosis, and Therapeutic Advances

This track will delve into the pathogenesis, diagnosis, and therapeutic advances in inflammatory breast cancer (IBC). Participants will gain insights into the unique characteristics of IBC, including its aggressive nature and distinctive clinical presentation. The discussions will focus on unraveling the underlying molecular mechanisms contributing to IBC development and progression. Diagnostic challenges, such as differentiating IBC from other breast malignancies, will be addressed, emphasizing the importance of accurate and timely diagnosis. Furthermore, cutting-edge therapeutic strategies and emerging treatment modalities specific to IBC will be explored, highlighting the latest advancements and clinical trials that aim to improve outcomes for patients with this challenging form of breast cancer.

Track-13: Pathological Assessment of Breast Reconstruction: Challenges and Surgical Considerations

The track on "Pathological Assessment of Breast Reconstruction: Challenges and Surgical Considerations" focuses on the complexities and unique aspects of assessing breast tissue following reconstructive procedures. This track explores the challenges faced by pathologists when evaluating post-reconstruction specimens, including distinguishing normal tissue from residual or recurrent cancer, identifying implant-associated changes, and interpreting the effects of radiation therapy. Additionally, it delves into the histopathological evaluation of various types of breast reconstructions, such as autologous flaps and implant-based reconstructions, addressing the impact of surgical techniques on pathological assessment. This track aims to enhance understanding, promote best practices, and foster collaboration between pathologists and reconstructive surgeons in optimizing the assessment of reconstructed breast tissue.

Track-14: Biomarkers and Predictive Factors in Breast Pathology: Translating Research into Clinical Practice Exploring the Spectrum: Advances in Breast Pathology

Biomarkers and Predictive Factors in Breast Pathology: Translating Research into Clinical Practice focuses on the critical role of biomarkers and predictive factors in breast pathology, aiming to bridge the gap between research discoveries and their practical application in clinical practice. The sessions within this track will explore the latest advancements in identifying and understanding biomarkers that aid in the diagnosis, prognosis, and treatment selection for breast cancer patients. From genomic and proteomic markers to hormone receptors and HER2/neu status, experts will discuss the clinical implications, validation studies, and guidelines for incorporating these biomarkers into routine practice. Attendees will gain valuable insights into how biomarkers and predictive factors are transforming breast pathology and enhancing personalized patient care.

Track-15: Multidisciplinary Approach to Breast Pathology: Collaboration between Pathologists, Radiologists, Surgeons, and Oncologists

"Multidisciplinary Approach to Breast Pathology: Collaboration between Pathologists, Radiologists, Surgeons, and Oncologists" emphasizes the significance of teamwork and cooperation among healthcare professionals involved in the diagnosis, treatment, and management of breast pathology. This track highlights the importance of integrating the expertise of pathologists, radiologists, surgeons, and oncologists to ensure comprehensive patient care. Discussions within this track will focus on effective communication, interdisciplinary tumor board meetings, shared decision-making, and the latest advancements in collaborative practices. By fostering a multidisciplinary approach, this track aims to enhance diagnostic accuracy, optimize treatment planning, and improve patient outcomes in the field of breast pathology.

Market Analysis of Breast Cancer

Breast cancer is a cancer that forms in the cells of the breasts. Breast cancer can occur in women and rarely in men. The symptoms of the breast cancer include a lump in the breast, bloody discharge from the nipple, changes in shape and size of the nipple or breast. There are 2 types of breast cancer: Non-invasive cancers stay within the milk ducts or lobules in the breast. They do not grow or invade in normal tissues within or beyond the breast. Non-invasive cancers are called as carcinoma in situ (in the same place) or pre-cancers. Invasive cancers do grow in normal, healthy tissues. Most breast cancers are invasive. Depending upon the type of cancer the treatment is determined, i.e., whether it is invasive or non-invasive cancer. Treatment varies depending upon the stage of cancer. It may consist of chemotherapy, surgery or radiation.

Early detection of breast cancer greatly increases the chances of successful treatment and saves the life. There are 2 major components of early detection of breast cancer: educate to promote early diagnosis and screening. There are 3 different types of screening tests available; they are the mammogram, clinical breast exam (CBE) and MRI (magnetic resonance imaging). 

Is Breast Cancer a Modern Illness?

Ancient Egyptians were the first to diagnose, treat and prevent breast cancer more than 3,500 years ago. Breast cancer is now the most well-known and researched cancers in the medical world today. People diagnosed with breast cancer at an early stage have a very good chance of a cancer-free future. But this was not the case earlier. The first case of any type of cancer documented in Egypt was a breast cancer in 1600 BC. Edwin Smith Papyrus, an ancient text found in 1860 in an Egyptian tomb, described 8 cases of ulcers or tumors of the breast. The first doctor, who attempted to treat this type of cancer, wrote: “There is no treatment!” Physicians and medical researchers in ancient period posited the following theories regarding the cause of the breast cancer: humoralism, punishment, divine, lack of sexual activity, physical injuries, fear of breast cancer, without the benefit of 21st-century diagnostics. In ancient times, they used to call it “the wandering womb” where they believed that the uterus could move throughout the body leaving health problems of every kind in its wake. It was not diagnosed until the 19th century, unless and until the cases of breast cancer increased. But the disease is somewhat controlled with improvement in sanitation and hence the lifespan of an individual is increased.

The first successful treatment for breast cancer was done by French surgeon Jean Louis Petit and later Scottish surgeon Benjamin Bell where the lymph nodes, breast tissue, and chest muscle are removed surgically. Surgeon William Stewart Halsted began performing and perfecting mastectomies around 1882. Halsted’s mastectomies were invasive where breasts, lymph nodes, and underlying muscles are being removed and the procedure was deemed necessary to prevent cancer from recurring but often left patients with severe pain and disability.

By the 1970’s, researchers began to develop lumpectomy- more limited surgery to remove only the cancerous tumor and any surrounding tissue affected by the tumor.

By 1985, researchers found that radiation followed by lumpectomy gave a chance of survival equal to the considerably move invasive mastectomy.

Around the 20th century, doctors used radiation therapy to shrink the cancerous cells. Chemotherapy became an option. It helped to shrink cancerous cells before surgery and prevent recurrence after surgery and treat cancer that is metastasized or has spread to other parts of the body. Scientists began to experiment with combined treatments to improve outcomes. Throughout the 1970’s, this procedure has been continued and this led to a better understanding of how cancer can develop and spread throughout the body. This understanding led to the development of more effective targeted treatments. This approach to treat cancer and research is still continuing today.

In 1923, the first large-scale review of women with breast cancer was done by English scientist Janet Lane-Claypon, which identified several risk factors that are still considered today.

In 1980’s and 1990’s, thousands of women undergoing breast cancer treatment and high dose bone marrow transplants hoping to have a good result, which turned it to a disaster after the loss of 15-20% of women’s life due to the treatment.

In 1995 report from the Nurses’ Health Study and 2002 results of research from the Women’s Health Initiative concluded that hormone replacement therapies which had become popular among menopausal women could significantly increase the risk of breast cancer.

In the late 1990’s, scientists found that certain variants of the genes BRCA1 and BRCA2 are associated with 80% of breast cancer risk. Some women who discover this gene mutation within their genetic makeup will take proactive steps to reduce their risk of cancer, including preemptive mastectomies and even hysterectomies.

As scientists deepen their understanding of the role of genetics in breast cancer risk, research on developing new techniques has been increased. Meanwhile, some research is being done on repair or even replaces harmful genes before breast cancer occurs.

As research continues to improve, there are several chances of every person to survive and can prevent breast cancer or any type of cancer. Taking healthy food, avoiding alcohol and smoking may be an important precaution from developing cancer. Regular self-exams and annual mammograms after 40 years old are recommended.

What’s New in Breast Cancer Research?

Treatments are being evaluated in trails. This includes individual drugs, the combination of drugs, surgical and radiation techniques.  Investigations include new types of cancer vaccines, targeted therapy, oncolytic virotherapy, and immunotherapy.

The latest research is reported annually at scientific meetings such as the American Society of Clinical Oncology, San Antonio Breast Cancer Symposium and St. Galen Oncology Conference, Switzerland. These studies are reviewed by professional societies and other organizations and formulated into guidelines for specific treatment groups and risk category.

Fenretinide, a retinoid (drugs related to vitamin A), is also being studied as a way to reduce the risk of breast cancer.

Cryoablation

As of 2014, cryoablation is being studied to see whether it could be the subtitle for lumpectomy in small cancers. There is tentative evidence in those with tumors less than 2 centimeters. It can also be used for those, surgery is not possible. Another review stated that cryoablation looks promising for early breast cancer of small size.

Breast cancer cell lines

A considerable part of the current knowledge on breast carcinomas is based on in vivo and in vitro studies, performed with cell lines derived from breast cancers. These provide an unlimited source of homogenous, self-replicating material, free of contaminating stromal cells and often easily cultured in simple standard media. The first breast cancer line described was BT-20, established in 1958. Since then, despite sustained work in this area, the number of permanent lines obtained has been strikingly low. Indeed, attempts to culture breast cancer cell lines from primary tumors have been largely unsuccessful. This poor efficiency was often due to technical difficulties associated with the extraction of viable tumor cells from their surrounding stroma. Most of the available breast cancer lines issued from metastatic tumors, mainly from a pleural effusion. Effusions provided generally large numbers of dissociated, viable tumor cells with little or no contamination by fibroblasts and other tumor stroma cells. Many of the currently used BCC lines were established in the late 1970’s. a very few of them, namely MCF-7, T-47D, and MDA-MB-231, account for more than two-thirds of all abstracts reporting studies on mentioned breast cancer cell lines, as concluded from a Medline-based survey.

Molecular markers

Transcription Factors

NFTA transcription factors are implicated in breast cancer, more specifically in the process of cell motility at the basis of metastasis formation. Indeed, NFAT1 (NFATC2) and NFAT5 are pro invasive and promigratory in breast carcinoma and NFAT3 (NFATC4) is an inhibitor of cell motility. NFAT1 regulates the expression of the TWEAKR and its ligand TWEAK with the Lipocalin 2 to increase breast cancer cell invasion and NFAT3 inhibits Lipocalin 2 expression to blunt the cell invasion.

Metabolic markers

Clinically, the most useful metabolic markers in breast cancer are the estrogen and progesterone receptors that are used to predict response to hormone therapy. New or potentially new markers for breast cancer include BRCA1 and BRCA2 to identify patients at high risk of developing breast cancer, HER2 and SCD1 for predicting response to therapeutic regimens and urokinase plasminogen activator, PA1-1 and SCD1 for assessing prognosis.

Survey Report

Breast cancer is the second leading cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. Breast cancer is most common after menopause. American Cancer Society, for the year 2016 estimates that about 252,710 new cases of invasive breast cancer will be diagnosed in women, about 63,410 new cases of carcinoma in situ (CIS) will be diagnosed and about 40,601 women will die from breast cancer.

Trends in breast cancer incidence

Incidence rates vary from 19.3 per 100 000 women in Eastern Africa to 89.9 per 100 000 women in Western Europe and are high in developed regions of the world (more than 80 per 100 000) except Japan and low in most of the developing regions (less than 40 per 100 000). Although developed countries have high incidence rates, in the transition countries like Latin America, it is going to be increased in the future. The rates vary worldwide, with Europe being the highest. The rates are increasing in Latin America and Asian countries mainly due to the population aging and screening practices.

The total number of cases registered for five year period 1998-2002 were 13 120 964 (6 848 973 men and 6 271 991 women), the average of annual cases registered to be about 1 250 000 for women and 1 369 795 for men. During this period, 1 775 353 cases of breast cancer were registered worldwide. The highest rates occurred in Europe (Belgium, France, Switzerland, Italy) and in Australia with average rates of 60-100/100 000 cases. The lowest ASR (W) was between 18-30/100 000 in India, Thailand, China and Africa (Harare and Kyadondo).

Canada Breast Cancer Statistics

26,300 women were diagnosed with breast cancer. This represents 25% of all new cancer cases in women in 2017.  5,000 women died from breast cancer. This represents 13% of all cancer deaths in women in 2017.

On average, 72 Canadian women were diagnosed with breast cancer every day. On average, 14 Canadian women died from breast cancer every day. 230 men were diagnosed with breast cancer and 60 died from breast cancer.

About 12% of Canadian women (1 in 8) will develop breast cancer over the course of her lifetime. In 2017, an estimated 266,110 new cases of invasive and 63,960 new cases of non-invasive (in situ) breast cancer are expected to be diagnosed.

After increasing incidence rates of breast cancer for the previous two decades, it began decreasing in the year 2000 and dropped by 7% from 2002 to 2003 alone. This decrease was partially due to the reduced use of hormone replacement therapy (HRT) by women after results of a large study called Women’s Health Initiative which was published in the year 2002. These results suggested a relation between HRT and increased breast cancer risk.

Though death rates have been decreased since 1989, about 40,610 women are expected to die in the year 2022 in the U.S. from breast cancer. Women under the age of 50 have experienced larger decreases. These decreases are thought to be the result of treatment advances, earlier detection through screening and increased awareness.

Besides skin cancer, breast cancer is the most commonly diagnosed cancer among American women. In 2022, it is estimated that about 30% of new cases diagnosed in women will be breast cancers.

Breast cancer is more common in African-American women than in white women under the age 45. Overall, African-American women are more likely to die of breast cancer. For Asian, Hispanic and Native-American women, the risk of developing and dying from breast cancer is lower. As many as 40 % cases more cases are predicted by 2030.

The risk of breast cancer in women doubles, if she has a first-degree relative (mother, sister or daughter) who has been diagnosed with breast cancer. Less than 15% of women who get breast cancer have a family member diagnosed with it.

About 5-10% of breast cancer is linked to gene mutations (abnormal changes) inherited from one’s mother or father. Mutations of BRCA1 and BRCA2 genes are the most common ones. On an average, women with the BRCA1 mutation have a 55-65% lifetime risk of developing breast cancer. The risk is 45% for the women with the BRCA2 mutation. Breast cancer that is positive for the BRCA1 and BRCA2 mutations tends to develop more often in younger women. An increased ovarian cancer risk is also associated with these genetic mutations. In men, BRCA2 mutations are associated with a lifetime breast cancer risk of about 6.8%, BRCA1 mutations are a less frequent cause of breast cancer in men.

The objective behind the Conference

The main objective of holding Breast Pathology and Cancer Diagnosis 2019 conference is to share the latest research and developments of individuals in the sphere of cancer, which helps to develop new techniques for the treatment and can also discuss and plan to reduce the use of chemotherapy treatment by introducing special drugs that will continue to develop and directly attack special targeted breast cancer cells.

Pharmaceutical Companies Leading the Breast Cancer Fight

• Bristol-Myers Squibb Co. (NYSE: BMY)
• Merck & Co. Inc. (NYSE: MRK)
• Medivation Inc. (NASDAQ: MDVN)
• Pfizer Inc. (NYSE: PFE)

Breast Cancer Associations & Societies around the Globe

1. American Cancer Society
2. American Medical Women's Association
3. American Society for Radiation Oncology
4. American Society of Paediatric Hematology/Oncology
5. Association of Cancer Physicians
6. Association of Chartered Physiotherapists in Women’s Health
7. Association of Women's Health, Obstetric and Neonatal Nurses
8. Breast Screen Australia Program
9. Cancer Relief Society Nepal
10. Cancer Society of Finland
11. Cancer Society of New Zealand
12. Caribbean Women's Health Association
13. European Association for Cancer Research (EACR)
14. Indonesian Society of Gynecologic Oncology
15. International Association for Women's Mental Health
16. International Gynecologic Cancer Society
17. Iranian Society of Radiation Oncology
18. Japanese Breast Cancer Society
19. New Zealand Breast Cancer Foundation (NZBCF)
20. Society for Women's Health Research
21. Spanish Association for Cancer Research (CMA)
22. Thai Gynecologic Cancer Society

Advantages of Participating at our conference:

• As an add on advantage the Speaker & Abstract pages created in Google on your profile under your name would get worldwide visibility.
• Our robust online publicity attracts 20000+ users and 60000+ views to our Library of Abstracts which brings worldwide exposure to the researchers and speakers participate in our conferences.
• All the conference participants can earn up to 16-18 CME Credits by participating at our Breast pathology 2024  Conference scheduled at Rome, Italy.
• To attain professional development we offer our participants a chance to earn up to 21 CPD Credits authorized by CPD Standards Office, UK by participating at our Breast pathology 2024.
•  All the conference participants will be awarded with IOCM Certification.
•  All the conference participants will have an unique opportunity to participate at One on One Meeting with Eminent Speakers.
•  A Unique opportunity to hear what the global researchers are talking about at our Keynote sessions by world’s most eminent researchers in the field of  Breast pathology 2024.
• Top Industries Representation of Industrial Leaders, where you get a great opportunity to meet and discuss with the Industrial Leaders in person.
• Thought provoking Symposia’s.
•  Workshops on Carrier Development.
•  Preconference workshops in all major countries.
•  Nominations for Best Poster Award.
•  Outstanding Young Researcher Award.
•  Group registration benefits.

Benefits of Participation | Speaker

• Explore the best in Cutting edge Research.
• Worldwide acknowledgment of Researcher’s profile.
• Obtain professional development credits.
• Your presence and talk will be recorded and hosted on YouTube and Video which in turn will gain potential value to your research profile.
• Make Lasting connections at Networking and Social Events.
• We provide unique convergence of Networking, Learning and Fun into a single package.
• An opportunity to give One page advertisement in abstract book and flyers distribution which eventually gets 1 Million views and add great value to your research profile.
• Learn beyond your field of interest, a change to know more about the new topics and research apart from your core subject.

Benefit of Participation | Sponsor

• Worlds No1 Platform to show case  Breast pathology 2024 Products.
• Exposure to the international atmosphere will increase the odds of getting new business.
• Opportunity to showcase the new technology, new products of your company, and/or the service your industry to a broad international audience.
• Attain with an exceptional format in showcasing the products and services and to gain the potential clients for the future business prospects.
• Our Breast pathology 2024 Conference in the one and only location to reach the top customers.
• Make new connections and fostering potential partnerships.
• Increase your business by lead generation through our conference participants.
• Build a successful business takes a lot of time, effort and drive, so it’s always good to have a network of colleagues and associates to draw energy from people who share a similar drive and objective.
• Flip side of learning new things is relearning classic techniques. Breast pathology 2024 conferences create opportunities for greater focus and reflection that could help you take your business to the next level.
• Benchmarking key strategies for business and moving it forward.
• Get answers to your business questions and challenges from credible individuals at our conference.
• Exposure and Networking Opportunity with the various top decision makers of the respective organizations, will eventually grow your business in Global market.
• Get to know more about your competitors are first-hand, learn more about their businesses, and discover their strengths and weaknesses, all of which can add to your business’s competitive edge.
• Encounter new vendors and suppliers for your business.
• Real Benefits in New business - Many Organizations make deals and sign contracts at our Breast pathology 2024.
• We offer you the Website visibility to more than 35K visitors in less than 6 months.
• Promotional logo of your organisation at our conference banner, website and other proceedings, branding and marketing material.
• Hosting session slots, poster awards, recognition in opening ceremony and complimentary registrations, exhibition/workshop booth, low-budget options.

Benefit of Association for Collaborators

• No one in the world have this huge visitors towards Breast pathology 2024, these is the best platform to show case your society.
• Create long-lasting relationships with the peers.
• Promotional content and Logo of your Association at our conference banner, website and other proceedings, branding and marketing material will increase your subscribers/Members number by 20 %.
• Our Website visibility to your Organization page can give a great impact for your association in the Global Market.
• Your representatives can network with key conference delegates to update their knowledge and understanding of your organization and services.
•  Details will be added to the conference press release where the details will be shared to < 100000 outlets.
•  Details will be incorporated in all conference promotional materials which will be distributed to Hospitals, Universities, Society and Researchers.

Benefits of Participation | Delegate

• Helps to meet Experts & Influencers Face to Face.
• Opportunities to meet researchers and experts of same field and share new ideas.
• Can help to know New Tips & Tactics.
• Professional Development – Elevate your knowledge and Skills.
• Conference attendance inspires, rejuvenates, and energizes delegates.
• Your participation at our conference will be helpful for a new approach and ideology that can be utilized for the extending the outcome of Companies or Industries.
• Enjoy the alluring city environment where the conference is being held.
• Raise your profile by being well-known

Visa Application Documents You should only apply for business visas to attend and attend conferences. Contact your nearest Rome, Italy Travel Agency/Visa Information Center/Embassy for the correct application form.

All visas for the visit to Rome, Italy are processed by the respective embassy authorities in the correct way only after the presentation of the corresponding documents.

If no documents are provided or if the guidelines are not followed, the competent authorities hold the right to reject/cancel the visas.

The minimum documents that may be required when applying for the visa from Rome, Italy include:

• Official Letter of Invitation
• Letter of Acceptance/Approval for abstracts (if you are a speaker)
• Proof of payment receipt for registration
• Hotel Booking Confirmation Letter for accommodation issued on conference letterhead

Note: For the Letter of Invitation and Accommodation Confirmation, payment of registration and accommodation fees is a prerequisite. Please contact us for more information
Email Id: [email protected]